These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 34733624)

  • 1. Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in
    Hirai N; Hatanaka Y; Hatanaka KC; Uno Y; Chiba SI; Umekage Y; Minami Y; Okumura S; Ohsaki Y; Sasaki T
    Transl Lung Cancer Res; 2021 Sep; 10(9):3737-3744. PubMed ID: 34733624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma.
    Ota T; Okabayashi A; Fukuoka M
    Respirol Case Rep; 2021 Oct; 9(10):e0841. PubMed ID: 34484797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression.
    Zhang H; Cong X; Yin J; Chen C; Liu Z
    Front Oncol; 2024; 14():1387388. PubMed ID: 38715777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E.
    Tan X; Wu Z; Chen M
    Onco Targets Ther; 2024; 17():307-312. PubMed ID: 38617091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of non-small cell lung cancer patients with non-V600E
    Lazar R; Fischbach C; Schott R; Somme L
    Front Oncol; 2024; 14():1307882. PubMed ID: 38601760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Unresectable
    Bapat N; Ferraro T; Esper L; Joshi AS; Haroun F; Baldwin CK
    JCEM Case Rep; 2024 Aug; 2(8):luae112. PubMed ID: 39081697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity.
    Bernstein A; Mrowczynski OD; Greene A; Ryan S; Chung C; Zacharia BE; Glantz M
    J Neurosurg; 2020 Dec; 133(6):1704-1709. PubMed ID: 31675726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAF
    Piringer G; Decker J; Trommet V; Kühr T; Heibl S; Dörfler K; Thaler J
    Front Oncol; 2023; 13():1166545. PubMed ID: 37213293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. POU5F1B is responsible for the acquired resistance to dabrafenib in papillary thyroid cancer cells with the BRAF V600E mutation.
    Li J; Yu Y
    Endocrine; 2024 Aug; ():. PubMed ID: 39136897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report.
    Fang R; Xu S; Gong J; Liao Z
    Onco Targets Ther; 2024; 17():27-31. PubMed ID: 38283732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report.
    Su PL; Lin CY; Chen YL; Chen WL; Lin CC; Su WC
    JTO Clin Res Rep; 2021 Aug; 2(8):100202. PubMed ID: 34590045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting.
    Hilhorst R; van den Berg A; Boender P; van Wezel T; Kievits T; de Wijn R; Ruijtenbeek R; Corver WE; Morreau H
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful dabrafenib and trametinib combination therapy in a patient with recurrent
    Nakamura E; Ota M; Matsuda R; Takeda M; Fujii T; Yamamoto Y; Hontsu S; Yamauchi M; Yoshikawa M; Muro S
    Respirol Case Rep; 2024 Jan; 12(1):e01277. PubMed ID: 38269311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective Treatment of Lung Adenocarcinoma With a Novel SLC44A1-BRAF Fusion Using Pembrolizumab Followed by Trametinib: A Case Report.
    Yasui S; Honda T; Onishi I; Ikeda S; Miyazaki Y
    Cureus; 2024 Feb; 16(2):e54739. PubMed ID: 38523924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exceptional Response in BRAF p.V600E-Mutant Enteric-Type Adenocarcinoma of the Lung With Cutaneous Spread: A Case Report.
    Sposito M; Scaglione IM; Eccher S; Pasqualin L; Avancini A; Colato C; Rosina P; Simbolo M; Caliò A; Scarpa A; Milella M; Pilotto S; Belluomini L
    JTO Clin Res Rep; 2023 Dec; 4(12):100597. PubMed ID: 38124787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photoinduced Conversion of Antimelanoma Agent Dabrafenib to a Novel Fluorescent BRAF
    Pinchuk B; von Drathen T; Opel V; Peifer C
    ACS Med Chem Lett; 2016 Oct; 7(10):962-966. PubMed ID: 27774137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilateral Spontaneous Supraspinatus Tendon Rupture Under Prolonged BRAF/MEK Targeting Treatment in a Melanoma Patient.
    Bafaloukos D; Gazouli I; Koutserimpas C; Skarlos PD; Samonis G
    Cureus; 2023 Dec; 15(12):e50567. PubMed ID: 38222175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.
    Loaiza-Bonilla A; Clayton E; Furth E; O'Hara M; Morrissette J
    Ecancermedicalscience; 2014; 8():479. PubMed ID: 25435907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficiency of B-RAF-/MEK-inhibitors in B-RAF mutated Ameloblastoma: Case report and review of literature.
    Büttner R; Gültekin SE; Heydt C; Nogova L; Meemboor S; Kreppel M; Aziz-Heiloun R
    Heliyon; 2023 Dec; 9(12):e23206. PubMed ID: 38149213
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.